Similar articles

• Enoxaparin for the prevention of venous thromboembolism.

  Calderon EJ, Varela JM, Gonzalez de la Puente MA. Calderon EJ, et al. N Engl J Med. 2000 Jan 13;342(2):136-7. N Engl J Med. 2000. PMID: 10636758 No abstract available.
• Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.

  Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW; THE-PRINCE Study Group. Kleber FX, et al. Am Heart J. 2003 Apr;145(4):614-21. doi: 10.1067/mhj.2003.189. Am Heart J. 2003. PMID: 12679756 Clinical Trial.
• Enoxaparin in neurosurgical patients.

  Connolly ES, Mocco J. Connolly ES, et al. N Engl J Med. 1998 Nov 26;339(22):1639-40. doi: 10.1056/NEJM199811263392213. N Engl J Med. 1998. PMID: 9867528 No abstract available.
• [Evidence for thrombosis prophylaxis to high-risk patients].

  Själander A, Jansson JH, Bergqvist D, Eriksson H, Svensson P. Själander A, et al. Lakartidningen. 2007 May 14-29;104(20-21):1585-7. Lakartidningen. 2007. PMID: 17564265 Review. Swedish. No abstract available.
• [Rivaroxaban (Xarelto): efficacy and safety].

  Rosencher N, Arnaout L, Chabbouh T, Bellamy L. Rosencher N, et al. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8. Ann Fr Anesth Reanim. 2008. PMID: 19185784 Review. French.